Detalles de la búsqueda
1.
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials.
Haematologica
; 109(1): 245-255, 2024 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37439329
2.
Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study.
Lancet Oncol
; 24(10): 1119-1133, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37717583
3.
Maintenance therapy in multiple myeloma: Two is not always better than one.
Br J Haematol
; 201(2): 181-182, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36541138
4.
Real-world assessment of treatment patterns and outcomes in patients with relapsed-refractory multiple myeloma in an Italian haematological tertiary care centre.
Br J Haematol
; 201(3): 432-442, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36648095
5.
Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma.
Blood
; 137(22): 3027-3036, 2021 06 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33739404
6.
Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel.
Haematologica
; 107(11): 2536-2547, 2022 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35861017
7.
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients.
Eur J Haematol
; 108(3): 178-189, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34716957
8.
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Lancet Oncol
; 22(12): 1705-1720, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34774221
9.
Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network.
Cancer
; 127(18): 3413-3421, 2021 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34181755
10.
Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP).
Ann Hematol
; 100(2): 429-436, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33161453
11.
Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs.
Haematologica
; 105(1): 193-200, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31221778
12.
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials.
Haematologica
; 105(4): 1074-1080, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31248973
13.
Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis.
Cancer
; 125(5): 750-760, 2019 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30561775
14.
'Real-life' analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study.
J Antimicrob Chemother
; 74(4): 1062-1068, 2019 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30649413
15.
Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies.
Haematologica
; 104(8): 1640-1647, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30733270
16.
Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM.
Blood
; 127(23): 2833-40, 2016 06 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27091875
17.
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma.
Blood
; 127(9): 1102-8, 2016 Mar 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-26729895
18.
A prospective observational study to assess clinical decision-making, prognosis, quality of life and satisfaction with care in patients with relapsed/refractory multiple myeloma: the CLARITY study protocol.
Health Qual Life Outcomes
; 16(1): 127, 2018 Jun 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-29914509
19.
A review discussing elotuzumab and its use in the second-line plus treatment of multiple myeloma.
Future Oncol
; 14(4): 319-329, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-29091475
20.
Autologous transplantation and maintenance therapy in multiple myeloma.
N Engl J Med
; 371(10): 895-905, 2014 Sep 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-25184862